Research guide · couples & PTSD
A small body of research has explored MDMA as an adjunct to PTSD-focused cognitive-behavioral conjoint therapy. The studies invite thoughtful attention—not broad conclusions about couples, relationships, or care availability.
This is an educational review of published research, not a treatment recommendation or a statement that a service is available.
CBCT, or cognitive-behavioral conjoint therapy, is a structured, trauma-focused therapy in which a person with PTSD and an intimate partner work together on PTSD education, relationship safety, communication, behavioral approach, and trauma- and relationship-related beliefs. The published studies below examined MDMA as an adjunct to that PTSD-focused framework; they did not study routine relationship enhancement for couples without a PTSD-related treatment target.
It is also important to keep the interventions distinct: none of the couples-CBCT studies described here used ketamine as an intervention. Research on one medicine or one therapy format is not evidence for a combined ketamine–MDMA approach.
This uncontrolled pilot included six couples, with one partner in each couple meeting PTSD criteria. In its condensed CBCT format, both partners received MDMA during two conjoint sessions. The authors reported pre–post and follow-up changes in PTSD and relationship measures through six months.
Six couples; no randomization, placebo, waitlist, or active comparator.This was a distinct, completed pilot of eight U.S. military-veteran couples. Only the veteran with PTSD received MDMA; partners participated in conjoint work and integration. The open-label report described pre–post improvement in PTSD and relationship measures, alongside variable relationship outcomes and moderate rebound during follow-up.
Eight dyads; single site, extensive screening, and no randomization or comparator.The 2026 follow-up picture was not uniform: only half of veterans and half of partners met both reliable and clinically significant relationship-improvement criteria, and one partner deteriorated. Those results are a reason to notice variability, not to turn a small uncontrolled result into a general couples claim.
Wagner et al. (2021) reported relational and growth outcomes from the same six dyads enrolled in the Monson 2020 pilot. It is a secondary analysis, not an independent replication or an additional six-couple trial. Reading both papers can add detail, but their findings should not be counted as two separate samples.
Across the two small pilots, any observed change could reflect the conjoint therapy, specialist teams, expectation, time, relationship context, or MDMA; the uncontrolled designs cannot isolate a cause. The evidence is PTSD-specific and does not establish effectiveness for couples generally, superiority to CBCT alone, or clinical availability.
NCT06044675 is a randomized study comparing MDMA-assisted CBCT with CBCT in dyads where one member has PTSD. Its active CBCT-only comparator is designed to answer a more informative question than an uncontrolled pre–post pilot. As of this guide’s evidence review, the trial was recruiting and has no reported efficacy results.
The completed eight-dyad veteran study was registered separately as NCT05979844; its 2026 article is the results report for that study, not another independent sample.
Early research can be meaningful without being a promise. These publications do not show that MDMA-assisted couples therapy is approved, appropriate for every couple, or offered by any particular organization. They also do not establish a ketamine–MDMA protocol. Keep the PTSD-specific context, small samples, different partner-exposure models, and local research and legal context in view.